TECFIDERA® (Dimethyl Fumarate) Data Reinforce Strong, Sustained Efficacy for Newly-Diagnosed MS Patients
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as Gulf tensions send oil to over six-week high
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Trump says Canada's Bombardier must build jets in US or lose market access
- European shares subdued as surging crude sharpens focus on ECB rate path
- Wall St slips as Gulf tensions send oil to over six-week high
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Baird Remains Buyers of Biogen (BIIB) Despite Kyle Bass Tecfidera Challenge
April 22, 2015 3:50 PM EDTBaird analyst Christopher Raymond weighed in on Biogen (NASDAQ: BIIB) this afternoon following news hedge fund manager Kyle Bass has filed an IPR against a Tecfidera patent.
The analyst said the challenge does not come as a surprise and they predicted this in February after... More
Kyle Bass files challenge to Biogen (BIIB) patent on Tecfidera - Bloomberg
April 22, 2015 11:13 AM EDTKyle Bass files challenge to Biogen (NASDAQ: BIIB) patent on Tecfidera - Bloomberg
... MoreBiogen Idec (BIIB) Announces Significant Data from TECFIDERA in MS
April 20, 2015 7:31 AM EDTBiogen Idec (NASDAQ: BIIB) announced new data that continue to support TECFIDERA® (dimethyl fumarate) as an effective, long-term treatment for people who are living with relapsing forms of multiple sclerosis (MS). Data show TECFIDERA significantly reduced relapses and disability progression in newly-diagnosed relapsing-remitting MS (RRMS) patients who had highly active disease. Additional data indicate TECFIDERA showed strong and sustained efficacy over five years in RRMS patients who... More
